Every GLP-1 receptor agonist sold before this one was a peptide, and a peptide swallowed whole is mostly digested before it is absorbed. That constraint is the whole reason the injection came first, and the reason the one oral peptide on the market arrives with a list of rules attached. Orforglipron is not a peptide, which removes the constraint and, with it, the rules — a different proposition from the tablets described in the oral-versus-injectable article.
The approval is real, and it is recent
Orforglipron is approved in the United States as Foundayo, under new drug application 220934, held by Eli Lilly and Company. Drugs@FDA records the original approval on April 1, 2026, with a supplement approved on August 4, 2026.[5] The labeled indication is use with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight plus at least one weight-related comorbid condition. The label's stated limitation of use is that concomitant use with another GLP-1 receptor agonist is not recommended.[5]
The approved ladder starts at 0.8 mg once daily, moves to 2.5 mg after at least 30 days, then to 5.5 mg after at least 30 more, and may rise through 9 mg and 14.5 mg to a maximum of 17.2 mg once daily. Tablets are swallowed whole, with or without food.[5] The escalation logic will look familiar from the titration article, but the interval is 30 days per step rather than 28, and there are six strengths rather than four or five.
The label's milligrams are not the papers' milligrams
This trips up anyone reading a trial and a listing side by side. The published phase 3 obesity trial reports doses of 6 mg, 12 mg and 36 mg. No Foundayo tablet carries any of those numbers. The label resolves it directly: effectiveness was established in trials of an investigational orforglipron formulation, and the label presents that trial data “shown as equivalent dosages of once daily Foundayo”.[5] The label's clinical-studies section therefore restates the same two trials as 5.5 mg, 9 mg and 17.2 mg.
The practical consequence is that a milligram figure alone identifies nothing. A product described as “orforglipron 36 mg” corresponds to no approved strength, and a product described in any form other than a swallowed tablet corresponds to no approved product at all.
What the obesity trial measured
ATTAIN-1 randomized 3,127 adults with obesity and without diabetes to once-daily orforglipron or placebo for 72 weeks. Mean change in body weight was −7.5% (95% CI, −8.2 to −6.8) at the low dose, −8.4% (95% CI, −9.1 to −7.7) at the middle dose and −11.2% (95% CI, −12.0 to −10.4) at the highest, against −2.1% (95% CI, −2.8 to −1.4) with placebo, with p < 0.001 for every comparison.[1]
In the highest-dose group, 54.6% lost 10% or more, 36.0% lost 15% or more, and 18.4% lost 20% or more, against 12.9%, 5.9% and 2.8% on placebo. Adverse events caused treatment discontinuation in 5.3% to 10.3% of orforglipron groups against 2.7% on placebo.[1] Those figures sit below what the weekly injections reached in their own trials, which is the comparison made in the semaglutide weight-loss article. No randomized head-to-head against an injection has been published.
The same ladder, a smaller effect, with diabetes
The label reports a second 72-week trial in 1,613 adults who had a body-mass index of 27 or higher and type 2 diabetes. At the top dose, weight fell 11.1% in the trial without diabetes and 9.6% in the trial with it. The responder gap is wider than the mean gap: 18.4% of the top-dose group without diabetes reached a 20% reduction, against 10.8% of the top-dose group with it.[5]
One cell in that table stops short of significance. In the diabetes trial, the 5.5-mg group's advantage over placebo at the 20% threshold was 1.8 percentage points (95% CI, −0.2 to 3.8) — a confidence interval that crosses zero, in the same table where every mean-weight comparison cleared p < 0.001.[5] The pattern that a GLP-1 does less for weight when diabetes is present is a general one, not a quirk of this molecule.
The drug's own glycemic trial, ACHIEVE-1, randomized 559 adults with early type 2 diabetes managed by diet and exercise alone to one of three doses or placebo for 40 weeks. From a mean baseline of 8.0%, glycated hemoglobin fell 1.48% at the highest dose against 0.41% on placebo, an estimated mean difference of −1.07 percentage points(95% CI, −1.33 to −0.81; p < 0.001), and body weight fell 7.6% against 1.7%.[2] No episodes of severe hypoglycemia were reported.[2]
No enhancer, and therefore no fasting window
Oral semaglutide solves the digestion problem chemically. Its tablet is coformulated with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, known as SNAC, which raises local pH in the stomach and protects the peptide from gastric enzymes long enough for some of it to cross.[4]That mechanism only works on an empty stomach, which is why the label instructs patients to take the tablet once daily in the morning with up to 4 ounces of water, with no other liquid, and to wait at least 30 minutes before eating, drinking or taking any other oral medication.[6]
Orforglipron needs none of that, because there is no peptide to protect. Its label says only to take it once daily with or without food and to swallow the tablet whole.[5] For a reader deciding between oral products, this is the substantive difference: not the dose, not the price, but whether a daily 30-minute fast has to fit into a morning. The oral products carried by sellers here are ranked on the oral board.
Better on the endpoint, worse on tolerability
The two oral drugs have been compared directly. ACHIEVE-3 randomized 1,698 adults with type 2 diabetes inadequately controlled on metformin to orforglipron or oral semaglutide for 52 weeks, open label, with non-inferiority as the primary objective. From a baseline glycated hemoglobin of 8.3%, the mean change was −1.91% on high-dose orforglipron against −1.47% on semaglutide 14 mg: an estimated treatment difference of −0.44 percentage points (95% CI, −0.62 to −0.26; p < 0.0001). Non-inferiority was met and superiority followed, including for low-dose orforglipron against semaglutide 14 mg at −0.24 percentage points (95% CI, −0.41 to −0.072; p = 0.0050).[3]
The safety columns of that trial run the other way. Gastrointestinal events affected 59% and 58% of the two orforglipron groups against 37% and 45% of the two semaglutide groups. Discontinuation for adverse events was 9% and 10% against 4% and 5%. Mean pulse rose 3.7 and 4.7 beats per minute on orforglipron against 1.0 and 1.5 on semaglutide.[3]A drug that wins the primary endpoint and loses three tolerability comparisons is not simply “better”, and the general shape of this trade is covered in the side-effects article.
A boxed warning the animal data did not produce
Foundayo carries the class boxed warning for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. The warning's own text records something unusual: orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, and the human relevance of the rodent finding that generated the class warning has not been determined.[5] The contraindication stands regardless, which is the conservative reading, and the underlying rodent signal is examined in the thyroid article.
What is still open
A separate phase 3b trial tested whether the tablet holds weight lost on an injection. It randomized 205 participants previously on tirzepatide and 171 previously on semaglutide. Among those who had reached a weight plateau, the orforglipron groups maintained 74.7% and 79.3% of their weight reduction at 52 weeks, against 49.2% and 37.6% on placebo, with estimated treatment differences of 25.5 (95% CI, 14.5 to 36.5) and 41.7 (95% CI, 24.4 to 59.0). The authors name the limitation plainly: there was no arm that simply continued the injection, and the trial ran one year.[7] What happens after stopping either drug is in the discontinuation article.
There is no published cardiovascular outcome trial for this molecule, no randomized comparison against an injectable, and no evidence beyond 72 weeks. And because an approved product now exists, the question a listing has to answer is narrow: is this the branded tablet, at a labeled strength, dispensed by a pharmacy against a prescription? Compounded preparations are not FDA-approved and receive no agency review of safety, efficacy or quality before they are dispensed — the distinction drawn in the compounded-versus-brand article — and for this molecule there is an approved alternative to compare any such offer against.